恩华药业(002262.SZ)取得右酮洛芬氨丁三醇注射液药品注册证书

Core Viewpoint - The company, Enhua Pharmaceutical, has received approval from the National Medical Products Administration for the registration of its injectable drug, R-ketorolac tromethamine, which is a non-steroidal anti-inflammatory analgesic used for acute moderate to severe postoperative pain in adults who are unsuitable for oral administration [1] Group 1 - The drug R-ketorolac tromethamine is an inhibitor of COX-1 and COX-2 activities [1] - It is intended to be used as an adjunct to opioid analgesics [1] - The approval signifies a potential expansion in the company's product offerings in the pain management segment [1]